Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Core One Labs Inc. CLABF OTC

Other OTC • Healthcare • Biotechnology • CA • USD

SharesGrow Score
22/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Core One Labs Inc. (CLABF) is a Biotechnology company in the Healthcare sector, currently trading at $0.00. It has a SharesGrow Score of 20/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $458,541, -46.9%/yr average growth. Net income is $16M (loss), growing at -21.8%/yr. Net profit margin is -3485.4% (negative). Gross margin is 90.8% (+104.1 pp trend).

Balance sheet: total debt is $0 against $7M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 0.81 (tight liquidity). Debt-to-assets is 0%. Total assets: $8M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 33/100 (Fail), Moat 50/100 (Partial), Future ?/100 (Fail), Income 10/100 (Fail).

CLABF SharesGrow Score Overview

27/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 50/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CLABF

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
CLABF: -46.9%/yr revenue is, -21.8%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✗
HEALTH Fail
33/100
Balance sheet CLABF: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 0.81 (tight liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
50/100
CLABF: Gross margin is 90.8% (+104.1 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
CLABF: Net profit margin is -3485.4%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.00001-0.20055
Volume71.76K
Avg Volume (30D)29.61K
Market Cap$500.00
Beta (1Y)0.51
Share Statistics
EPS (TTM)-0.49
Shares Outstanding$32.71M
IPO Date2015-06-25
CEOJoel Shacker
Financial Highlights & Ratios
Revenue (TTM)$458.54K
Gross Profit$416.34K
EBITDA$-7.8M
Net Income$-15.98M
Operating Income$-7.84M
Total Cash$736.48K
Net Debt$-626.48K
Total Assets$8.11M
Price / Earnings (P/E)-0
Price / Sales (P/S)0
Analyst Forecast
Company Info
CountryCA
ExchangeOther OTC
CurrencyUSD
ISINCA21872J3073

Price Chart

Track all markets on TradingView
CLABF
Core One Labs Inc. ↗  ·  Other OTC
Healthcare • Biotechnology
0.00 52WK RANGE 0.20

People Also View

OPT
OPT
Opthea Limited
$3.41
+1.49%
 ASCLF
ASCLF
Ascletis Pharma Inc.
$2.10
+0.00%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$30.42
+11.35%
 INBX
INBX
Inhibrx Biosciences, Inc.
$83.60
+0.49%
 ELYM
ELYM
Eliem Therapeutics, Inc.
$5.11
-0.97%
 NGM
NGM
NGM Biopharmaceuticals, Inc.
$1.54
-1.28%
 GNLX
GNLX
Genelux Corporation
$2.84
+7.58%
 ANEB
ANEB
Anebulo Pharmaceuticals, Inc.
$0.50
+0.00%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message